IP Library Granted Patent US 9,901,576
Granted Patent B2
US 9,901,576 · App. 15/355,868 · Granted Feb 27, 2018

Stable formulation of phenobarbital sodium injection

Inventors: Michael G. Parker (Cherry Hill, NJ); Scott S. Wilson (Cherry Hill, NJ); Yasmeen Chahal (Cherry Hill, NJ); Kelly W. Hovius (Cherry Hill, NJ); David E. McAnany (Cherry Hill, NJ)
Assignee: West-Ward Pharmaceuticals International Limited
A61K31/515A61J1/06A61K9/0019A61K9/08A61K47/10B65B3/003B65B7/16B65B55/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,901,576
App. No.
15/355,868
Granted
Feb 27, 2018
Kind
B2
Abstract

Stable phenobarbital sodium solutions for injection that do not generate impurities during extended storage. These solutions include phenobarbital sodium in an amount of 15 to 200 mg/mL; a C1-C4 alcohol such as ethanol in an amount of 105 to 160 mg/mL; and a glycol such as propylene glycol in an amount of between 620 and 830 mg/mL and have a pH of between 9 and 12 which is adjusted to that range by adding acid or base, as required. No more than 50 mg/mL water is present including any water introduced by the acid or base. The solutions contain no more than 0.8% of phenyl ethyl acetyl urea impurity as well as no detectable amount of phenyl butyric acid after two years storage at room temperature.

Claims (51)

1. A phenobarbital sodium solution for injection comprising:

phenobarbital sodium in an amount of 15 to 200 mg/mL;

a C1-C4 alcohol in an amount of 105 to 160 mg/mL; and

propylene glycol in an amount of between 620 and 830 mg/mL;

wherein the solution has a pH of between 9 and 12 which is adjusted to that range by adding a sufficient amount of acid or base, as required;

wherein the solution contains no more than 50 mg/mL water including any water introduced by the acid or base that is added to provide the desired pH; and

wherein the solution contains no more than 0.8% of phenyl ethyl acetyl urea (PEAU) impurity after two years storage at room temperature.

2. The solution of claim 1 , wherein:

the phenobarbital sodium is present in an amount of 25 to 150 mg/mL;

the C1-C4 alcohol is present in an amount of 125 to 150 mg/mL; and

the propylene glycol is present in an amount of between 675 and 830 mg/mL; and

the solution has a pH of between 9.1 and 10.2.

3. The solution of claim 1 , wherein:

the phenobarbital sodium is present in an amount of 25 to 90 mg/mL;

the C1-C4 alcohol is ethanol and is present in an amount of about 140 mg/mL; and

the polypropylene glycol is present in an amount of between 730 and 830 mg/mL;

wherein the solution contains no more than 40 mg/mL water.

4. The solution of claim 1 , wherein:

the phenobarbital sodium is present in an amount of 90 to 150 mg/mL;

the C1-C4 alcohol is ethanol and is present in an amount of about 140 mg/mL; and

the polypropylene glycol is present in an amount of between 660 and 785 mg/mL;

wherein the solution contains no more than 40 mg/mL water.

5. The solution of claim 1 which is free of preservatives or antioxidants.

6. The solution of claim 1 which does not contain a detectable amount of phenyl butyric acid (PBA) after two years storage at room temperature.

7. The solution of claim 1 which does not contain any other drug active.

8. The solution of claim 1 which consists of the recited components.

9. The solution of claim 1 specifically as the following formulations:

(a) the phenobarbital sodium is present in an amount of 25 mg/mL;

the C1-C4 alcohol is ethanol and is present in an amount of about 140 mg/mL;

the polypropylene glycol is present in an amount of about 809 mg/mL; and

wherein the solution contains no more than 40 mg/mL water; or

(b) the phenobarbital sodium is present in an amount of 55 mg/mL;

the C1-C4 alcohol is ethanol and is present in an amount of about 140 mg/mL;

the polypropylene glycol is present in an amount of about 779 mg/mL; and

wherein the solution contains no more than 40 mg/mL water; or

(c) the phenobarbital sodium is present in an amount of 90 mg/mL;

the C1-C4 alcohol is ethanol and is present in an amount of about 140 mg/mL;

the polypropylene glycol is present in an amount of about 754 mg/mL; and

wherein the solution contains no more than 40 mg/mL water; or

(d) the phenobarbital sodium is present in an amount of 150 mg/mL; and

the C1-C4 alcohol is ethanol and is present in an amount of about 140 mg/mL;

the polypropylene glycol is present in an amount of about 694 mg/mL; and

wherein the solution contains no more than 40 mg/mL water.

10. A sealed container that includes therein about 0.5 to about 20 mL of the phenobarbital sodium solution of claim 1 .

11. The sealed container of claim 10 which is sterilized.

12. The sealed container of claim 10 which is a syringe or vial.

13. The sealed container of claim 10 which has a headspace that has an oxygen content of less than 10% by volume or less than 5% by volume.

14. A method for making the phenobarbital sodium solution according to claim 1 which comprises admixing the phenobarbital sodium with the alcohol and glycol and then adjusting the pH to the desired range as necessary by the addition of the acid or base.

15. The method of claim 14 which further comprises filling a container with about 0.5 to about 20 mL of the solution; and sealing the container.

16. The method of claim 14 which further comprises sterilizing the container and sealing the sterilized container.

17. The method of claim 14 which further comprises providing a headspace in the sealed container that contains oxygen in an amount of less than 10% by volume or less than 5% by volume by adding nitrogen to the container.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2023
From: WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED
To: HIKMA PHARMACEUTICALS USA INC.
Reel/Frame 065483/0819 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2017
From: PARKER, MICHAEL G.; WILSON, SCOTT S.; CHAHAL, YASMEEN; HOVIUS, KELLY W.; MCANANY, DAVID E.
To: WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 041988/0062 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2017
From: EUROHEALTH INTERNATIONAL SARL
To: WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 041968/0707 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2016
From: PARKER, MICHAEL G.; WILSON, SCOTT S.; CHAHAL, YASMEEN; HOVIUS, KELLY W.; MCANANY, DAVID E.
To: EUROHEALTH INTERNATIONAL SARL
Reel/Frame 041113/0634 →
Continuity (2)
Provisional Application 62258000 · Nov 20, 2015
Related Publication 20170143719A1 · May 25, 2017